BOPI 06 BR / 2025 REPERTOIRE NUMERIQUE 14 Fig. 3 ________________________________________ (11) 21922 Consulter le mémoire (51) A61K 39/40 (2023.01); A61P 31/04 (2023.01); C07K 16/12 (2023.01); C12N 15/13 (2023.01); G01N 33/68 (2023.01) (21) 1202300388 - PCT/CN2022/082011 (22) 21/03/2022 (30) CN n° 202110301731.X du 22/03/2021 (54) Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof. (72) AN, Maomao (CN); QIU, Xiran (CN); CHEN, Simin (CN); GUO, Shiyu (CN) et LI, Bohua (CN) (73) 1-STARMAB BIOLOGICS (SUZHOU) CO., LTD, Room 208, Building 2 No. 40, Suhong West Road, Suzhou Industrial Park, SUZHOU, Jiangsu 215101 (CN) et 2-STARMAB BIOLOGICS (SHANGHAI) CO., LTD, Building 3 and 4, No. 2666 Panjing Road, Baoshan District, SHANGHAI 201908 (CN) (74) ALEMBONG OSWALD AMIN, S/C VON SEIDELS CAMEROON SARL, Suite 516 Commercial Bank Building, Quartier Intendance (adjacent Espace Landmark), B.P. 30188, YAOUNDE (CM). (57) Provided is an isolated antigen-binding protein, which comprises at least one CDR in an antibody heavy chain variable region VH, wherein the VH comprises the amino acid sequence as shown in SEQ ID NO: 39. The isolated antigen-binding protein can specifically bind to streptococcus pneumoniae hemolysin protein and a variant thereof. Further provided is the use of the isolated antigen-binding protein in the prevention and/or treatment of diseases and/or conditions of a streptococcus pneumoniae infection. Fig. 2 ________________________________________ (11) 21923 Consulter le mémoire (51) A01N 43/56 (2018.01); A01N 43/647 (2018.01); A01N 43/82 (2018.01); A61K 31/443 (2018.01); A61K 31/4436 (2018.01); A61K 31/4439 (2018.01); C07D 401/04 (2018.01); C07D 405/14 (2018.01); C07D 417/04 (2018.01) (21) 1202300485 - PCT/US2022/034647 (22) 23/06/2022 (30) US n° 63/214,420 du 24/06/2021
RkJQdWJsaXNoZXIy MTM1NDc3MA==